Envoy Medical Receives Another European Patent for its Modular Cochlear Implant System
Envoy Medical (NASDAQ: COCH) has been granted European Patent No. 3858425 for its modular cochlear implant system. The patent covers technology for a cochlear implant system capable of receiving input signals from both an implantable source and a wireless receiving device. The system can output stimulation signals based on these inputs using a programmable mixing ratio that determines the relative contributions of each input signal.
Envoy Medical (NASDAQ: COCH) ha ricevuto il Brevetto Europeo n. 3858425 per il suo sistema di impianto cocleare modulare. Il brevetto copre la tecnologia di un sistema di impianto cocleare in grado di ricevere segnali di input sia da una sorgente impiantabile che da un dispositivo di ricezione wireless. Il sistema può generare segnali di stimolazione basati su questi input utilizzando un rapporto di miscelazione programmabile che determina i contributi relativi di ciascun segnale di input.
Envoy Medical (NASDAQ: COCH) ha recibido la patente europea No. 3858425 para su sistema modular de implante coclear. La patente cubre la tecnología de un sistema de implante coclear capaz de recibir señales de entrada tanto de una fuente implantable como de un dispositivo receptor inalámbrico. El sistema puede emitir señales de estimulación basadas en estas entradas utilizando una proporción de mezcla programable que determina las contribuciones relativas de cada señal de entrada.
Envoy Medical (NASDAQ: COCH)는 모듈식 인공 와우 이식 시스템에 대해 유럽 특허 번호 3858425를 부여받았습니다. 이 특허는 이식 가능한 소스와 무선 수신 장치 모두에서 입력 신호를 수신할 수 있는 인공 와우 이식 시스템의 기술을 다룹니다. 이 시스템은 이러한 입력에 기반하여 자극 신호를 출력할 수 있으며, 각 입력 신호의 상대적 기여를 결정하는 프로그래머블 혼합 비율을 사용합니다.
Envoy Medical (NASDAQ: COCH) a reçu le brevet européen n° 3858425 pour son système d'implant cochléaire modulaire. Le brevet couvre la technologie d'un système d'implant cochléaire capable de recevoir des signaux d'entrée à la fois d'une source implantable et d'un dispositif de réception sans fil. Le système peut générer des signaux de stimulation en fonction de ces entrées en utilisant un rapport de mélange programmable qui détermine les contributions relatives de chaque signal d'entrée.
Envoy Medical (NASDAQ: COCH) wurde das europäische Patent Nr. 3858425 für sein modulares Cochlea-Implantatsystem erteilt. Das Patent umfasst die Technologie eines Cochlea-Implantatsystems, das in der Lage ist, Eingangssignale sowohl von einer implantierbaren Quelle als auch von einem drahtlosen Empfangsgerät zu empfangen. Das System kann stimulierende Signale basierend auf diesen Eingaben ausgeben, indem es ein programmierbares Mischungsverhältnis verwendet, das die relativen Beiträge jedes Eingangssignals bestimmt.
- Secured new European patent strengthening intellectual property portfolio
- Patent protection for innovative cochlear implant technology in European market
- None.
Insights
This patent grant represents an incremental step in Envoy Medical's IP portfolio but has immediate financial impact. The modular cochlear implant system's technology, allowing programmable mixing of input signals, shows technical advancement in implantable hearing solutions. However, several key considerations temper the immediate significance:
The European patent provides protection for the technology but doesn't guarantee market success or revenue generation. The path from patent to commercialization typically requires significant additional development, regulatory approvals and market penetration efforts. For a company with a
The mixing ratio functionality could potentially improve sound quality and user experience, differentiating their product in the competitive cochlear implant market. Yet, actual market impact depends on successful product development, clinical validation and market acceptance.
WHITE BEAR LAKE, Minnesota, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. (“Envoy Medical”) (NASDAQ: “COCH”), a hearing health company focused on fully implanted hearing systems, today announces that the European Patent Office has granted the Company Patent No. 3858425, titled,” Implantable Modular Cochlear Implant System with Communication System and Network.”
The patent relates to a modular cochlear implant system configured to receive input signals from an implantable source and a wireless receiving device and output a stimulation signal based on the received input signals and a programmable mixing ratio representative of the relative contributions of the input signals to the stimulation signal.
About the Fully Implanted Acclaim® Cochlear Implant
We believe the fully implanted Acclaim Cochlear Implant (“Acclaim CI”) is a first-of-its-kind hearing device. Envoy Medical’s fully implanted technology includes a sensor designed to leverage the natural anatomy of the ear instead of a microphone to capture sound.
The Acclaim CI is designed to address severe to profound sensorineural hearing loss that is not adequately addressed by hearing aids. The Acclaim CI is expected to be indicated for adults who have been deemed adequate candidates by a qualified physician.
The Acclaim Cochlear Implant received the Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) in 2019.
CAUTION The fully implanted Acclaim Cochlear Implant is an investigational device. Limited by Federal (or United States) law to investigational use.
About the Esteem® Fully Implanted Active Middle Ear Implant (FI-AMEI)
The Esteem fully implanted active middle ear implant (FI-AMEI) is the only FDA-approved, fully implanted* hearing device for adults diagnosed with moderate to severe sensorineural hearing loss allowing for 24/7 hearing capability using the ear’s natural anatomy. The Esteem FI-AMEI hearing implant is invisible and requires no externally worn components and nothing is placed in the ear canal for it to function. Unlike hearing aids, you never put it on or take it off. You can’t lose it. You don’t clean it. The Esteem FI-AMEI hearing implant offers true 24/7 hearing.
*Once activated, the external Esteem FI-AMEI Personal Programmer is not required for daily use.
Important safety information for the Esteem FI-AMEI can be found at: https://www.envoymedical.com/safety-information.
Additional Information and Where to Find It
Copies of the documents filed by Envoy Medical with the SEC may be obtained free of charge at the SEC’s website at www.sec.gov.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-Looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “target” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking. Such statements may include, but are not limited to, statements regarding the expectations of Envoy Medical concerning the outlook for its business, productivity, plans and goals for future operational improvements and capital investments; the Acclaim CI being the first to market fully implanted cochlear implant, the timing of IRB approvals, site activations, enrollment, and beginning of Envoy Medical’s clinical trial, the timing of and FDA’s position related to expanding the clinical trial to full cohort, the result of the clinical trial, the timing and results of clinical trials of the Acclaim CI, and the participation of any institution in such trials; the safety, performance, and market acceptance of the Acclaim CI; and any information concerning possible or assumed future operations of Envoy Medical. The forward-looking statements contained in this press release reflect Envoy Medical’s current views about future events and are subject to numerous known and unknown risks, uncertainties, assumptions and changes in circumstances that may cause its actual results to differ significantly from those expressed in any forward-looking statement. Envoy Medical does not guarantee that the events described will happen as described (or that they will happen at all). These forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to changes in the market price of shares of Envoy Medical’s Class A Common Stock; changes in or removal of Envoy Medical’s shares inclusion in any index; Envoy Medical’s success in retaining or recruiting, or changes required in, its officers, key employees or directors; unpredictability in the medical device industry, the regulatory process to approve medical devices, and the clinical development process of Envoy Medical products; competition in the medical device industry, and the failure to introduce new products and services in a timely manner or at competitive prices to compete successfully against competitors; disruptions in relationships with Envoy Medical’s suppliers, or disruptions in Envoy Medical’s own production capabilities for some of the key components and materials of its products; changes in the need for capital and the availability of financing and capital to fund these needs; changes in interest rates or rates of inflation; legal, regulatory and other proceedings could be costly and time-consuming to defend; changes in applicable laws or regulations, or the application thereof on Envoy Medical; a loss of any of Envoy Medical’s key intellectual property rights or failure to adequately protect intellectual property rights; the effects of catastrophic events, including war, terrorism and other international conflicts; and other risks and uncertainties set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward Looking Statements” in the Annual Report on Form 10-K filed by Envoy Medical on April 1, 2024, and in other reports Envoy Medical files, with the SEC. If any of these risks materialize or Envoy Medical’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While forward-looking statements reflect Envoy Medical’s good faith beliefs, they are not guarantees of future performance. Envoy Medical disclaims any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, new information, data or methods, future events or other changes after the date of this press release, except as required by applicable law. You should not place undue reliance on any forward-looking statements, which are based only on information currently available to Envoy Medical.
###
Investor Contact:
CORE IR
516-222-2560
investorrelations@envoymedical.com
FAQ
What is the new European patent number granted to Envoy Medical (COCH)?
What technology does Envoy Medical's (COCH) new European patent cover?
When did Envoy Medical (COCH) receive its latest European patent?
